Clinical studies explored the potential of Epo to interfere with cell loss in neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (Maiese et al., 2008; Chong et al., 2013; Rey et al., 2019). Here, EPO is linked to neurodegenerative disease.